{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Brainstorm Cell Therapeutics Inc."},"Symbol":{"label":"Symbol","value":"BCLI"},"Address":{"label":"Address","value":"1325 AVENUE OF AMERICAS,28TH FLOOR, NEW YORK, New York, 10019, United States"},"Phone":{"label":"Phone","value":"+1 201 488-0460"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases."},"CompanyUrl":{"label":"Company Url","value":"https://www.brainstorm-cell.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bob Dagher","title":"Chief Medical Officer & Executive Vice President"},{"name":"Chaim Lebovits","title":"President & Chief Executive Officer"},{"name":"Hartoun Hartounian","title":"Chief Operating Officer & Executive Vice President"},{"name":"Netta Blondheim-Shraga","title":"Vice President-Research & Development"},{"name":"Yael Gothelf","title":"Vice President-Scientific & Regulatory Affairs"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}